Compare IDEXX Laboratories, Inc. (IDXX) vs Vanguard S&P 500 Growth Index Fund ETF (VOOG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Vanguard S&P 500 Growth Index Fund ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Vanguard S&P 500 Growth Index Fund ETF trades at $87.27 (market cap $27.10B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Vanguard S&P 500 Growth Index Fund ETF is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Vanguard S&P 500 Growth Index Fund ETF for 54 Days on average.
| IDXX | VOOG | |
|---|---|---|
Market Cap | $40.43B | $27.10B |
Volume | 692,164 | 1,178,312 |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $87.81 |
52-Week Low | $504.70 | $65.32 |
Typical Hold Time | 46 Days | 54 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
VOOG trades at $87.29, down 0.46% on the day, maintaining a bullish technical stance with strong moving average support. The ETF holds 148 large-cap growth stocks from the S&P 500, with significant technology sector exposure. Recent institutional buying activity from firms like Integrated Wealth Concepts and NewEdge Advisors signals confidence in the growth-focused strategy. Technical indicators show bullish momentum with key support at $85 and resistance at $88.
VOOG's long-term growth potential remains compelling with 400% returns over the past decade and 14% gains year-to-date. The ETF's low 0.07% expense ratio and focus on high-performing growth stocks provide cost-effective exposure to market leaders. However, concentration in technology stocks and sensitivity to interest rate changes present risks. The current neutral oscillator readings suggest potential for consolidation near recent highs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Vanguard S&P 500 Growth Index Fund ETF
VOOG is an index-based ETF that tracks the S&P 500 Growth Index, composed of the growth-oriented companies within the S&P 500. It selects constituents based on three key metrics—sales growth, the ratio of earnings change to price, and momentum—offering a highly liquid and low-cost way to capture the high-performing 'growth slice' of the broader U.S. large-cap market.
Read more on VOOG →
